Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins
<p>Abstract</p> <p>An explanation for the higher incidence of cardiovascular disease and heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) with doxazosin and the Vasodilator Heart Failure Trial (V-HeFT) with prazosin might be...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2001-09-01
|
Series: | Current Controlled Trials in Cardiovascular Medicine |
Subjects: | |
Online Access: | http://dx.doi.org/10.1186/cvm-2-6-251 |
id |
doaj-d9124a7a06c74939a0f993ede9f60f72 |
---|---|
record_format |
Article |
spelling |
doaj-d9124a7a06c74939a0f993ede9f60f722020-11-24T22:13:26ZengBMCCurrent Controlled Trials in Cardiovascular Medicine1468-67082001-09-012625125310.1186/cvm-2-6-251Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteinsHooper Philip L<p>Abstract</p> <p>An explanation for the higher incidence of cardiovascular disease and heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) with doxazosin and the Vasodilator Heart Failure Trial (V-HeFT) with prazosin might be decreased expression of heat shock proteins. Heat shock proteins help to protect cells from ischemic injury by decreasing oxidation, suppressing cytokine action, refolding damaged proteins, and decreasing apoptosis. I hypothesize that α-adrenergic blockade decreases heat shock protein levels, thus making the heart and vascular system vulnerable to injury from pathologic processes such as ischemia, hypertension, oxidation or inflammation. Similarly, poor cardiovascular outcomes with calcium-channel blockers might be due to decreased expression of heat shock proteins.</p> http://dx.doi.org/10.1186/cvm-2-6-251α-adrenergic blockerscalcium-channel blockerscongestive heart failuredoxazosinheat shock proteins |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hooper Philip L |
spellingShingle |
Hooper Philip L Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins Current Controlled Trials in Cardiovascular Medicine α-adrenergic blockers calcium-channel blockers congestive heart failure doxazosin heat shock proteins |
author_facet |
Hooper Philip L |
author_sort |
Hooper Philip L |
title |
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins |
title_short |
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins |
title_full |
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins |
title_fullStr |
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins |
title_full_unstemmed |
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins |
title_sort |
hypothesis to explain poor outcomes in the allhat and v-heft trials: decreased expression of heat shock proteins |
publisher |
BMC |
series |
Current Controlled Trials in Cardiovascular Medicine |
issn |
1468-6708 |
publishDate |
2001-09-01 |
description |
<p>Abstract</p> <p>An explanation for the higher incidence of cardiovascular disease and heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) with doxazosin and the Vasodilator Heart Failure Trial (V-HeFT) with prazosin might be decreased expression of heat shock proteins. Heat shock proteins help to protect cells from ischemic injury by decreasing oxidation, suppressing cytokine action, refolding damaged proteins, and decreasing apoptosis. I hypothesize that α-adrenergic blockade decreases heat shock protein levels, thus making the heart and vascular system vulnerable to injury from pathologic processes such as ischemia, hypertension, oxidation or inflammation. Similarly, poor cardiovascular outcomes with calcium-channel blockers might be due to decreased expression of heat shock proteins.</p> |
topic |
α-adrenergic blockers calcium-channel blockers congestive heart failure doxazosin heat shock proteins |
url |
http://dx.doi.org/10.1186/cvm-2-6-251 |
work_keys_str_mv |
AT hooperphilipl hypothesistoexplainpooroutcomesintheallhatandvhefttrialsdecreasedexpressionofheatshockproteins |
_version_ |
1725801101576372224 |